巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    4D Molecular Therapeutics

    FDMT
    9.340
    0.200
    2.10%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・4D Molecular Therapeutics - 延遲價格・最後更新於 16/08 9:30
    最高位
    9.560
    最低位
    9.200
    開市價
    --
    前收市價
    9.540
    成交量(千)
    2.36
    成交額(百萬)
    0.19
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    302.45
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    36.140 - 5.320
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    4D Molecular Therapeutics
    證券代碼
    FDMT.US
    所屬板塊
    Biotechnology
    公司業務
    4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
    發行量
    32299784
    公司總部
    5858 Horton Street, Suite 455
    公司網址
    https://www.4dmoleculartherapeutics.com
    公司電郵
    info@4dmt.com
    公司電話
    +1 510 505-2680
    暫無內容

    關於

    4D Molecular Therapeutics(FDMT.US)所屬的行業板塊為Biotechnology。
    4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
    詳細公司背景可參考: https://www.4dmoleculartherapeutics.com